- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04173130
Monocentric Feasibility Study for a New Medical Device for the Treatment of Anal Fissure With Botulinum Toxin
Étude Monocentrique de faisabilité d'un Nouveau Dispositif Pour le Traitement de la Fissure Anale Par Toxine Botulique (FR) Monocentric Feasibility Study for a New Medical Device for the Treatment of Anal Fissure With Botulinum Toxin (EN)
Study Overview
Detailed Description
Anal fissure is a common anal disease. This is a longitudinal tear in the distal part of the anal canal. The fissure provokes a spasm of the internal anal sphincter and as such pain and eventually bleeding.
There are currently 3 different treatments. All available treatments tend to relax the anal sphincter, which reduces pain and promotes fissure healing.
The first treatment consists in the local application of cream into the anal canal.
The second option is the injection of botulinum toxin into the internal or external anal sphincter. Finally the third option is a surgical intervention, most frequently a lateral sphincterotomy.
Although the usefulness of botulinum toxin to treat anal fissure has been demonstrated, the results vary. This is most likely largely due to the fact that there is no standardized way to inject botulinum toxin and that there is a significant learning curve. In addition, the gesture is not without risk for the operator.
The objective of the study is to assess the feasibility of injecting botulinum toxin into the anal canal with a new medical device for patients with anal fissure.
The trial is a mono-centric pilot study conducted on 4 patients. The study is open, prospective and all patients will be treated with the botulinum toxin injected using the new medical device.
The device (single-use) under investigation and the botulinum toxin will be made available free of charge to the patient.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Vaud
-
Lausanne, Vaud, Switzerland, 1011
- Lausanne Universitary Hospital (CHUV)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adult patients suffering from anal fissures for a minimum of 6 weeks.
- informed consent signed
Exclusion Criteria:
- Contraindication to the use of botulinum toxin or any known allergies
- Pregnant or breastfeeding women
- Immune deficiency, immunosuppression
- Anticoagulant treatment
- Previous pelvic radiotherapy
- Acute anal inflammation (eg.proctitis)
- Internal hemorrhoids of grade 2 or higher
- Anal fissure that did not respond to a previous treatment by botulinum toxin
- History of lateral sphincterotomy
- Cardiopulmonary disease leading to reduced function of the Cardiopulmonary system
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Injection of botulinum toxin with investigational device
|
Injection of botulinum toxin into the anal sphincter with the investigational device (anuscope with needles).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of the injection of the botulin toxin with the device under investigation
Time Frame: This outcome will be assessed right after the use of the device under investigation, at day 1 (day of the intervention).
|
The operator shall answer by yes or no.
If yes, the procedure is further assessed (see outcome 2)
|
This outcome will be assessed right after the use of the device under investigation, at day 1 (day of the intervention).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of the procedure by the operator
Time Frame: This outcome will be assessed right after the use of the device under investigation, at day 1 (day of the intervention).
|
The operator will assess the procedure by answering the following questions: How was the introduction of the anuscope ? easy-neither easy nor difficult-difficult. How was the positioning of the anuscope? easy-neither easy nor difficult-difficult. How was the deployment of the needles? easy-neither easy nor difficult-difficult. How was the injection of the toxin? easy-neither easy nor difficult-difficult. How was the needles retraction? easy-neither easy nor difficult-difficult. |
This outcome will be assessed right after the use of the device under investigation, at day 1 (day of the intervention).
|
Assessment of the patient's tolerance: visual analogic scale (VAS)
Time Frame: This outcome will be assessed right after the use of the device under investigation, at day 1 (day of the intervention).
|
Patient assessment using a visual analogic scale (0 to 10, 0 not tolerated at all, 10 well tolerated)
|
This outcome will be assessed right after the use of the device under investigation, at day 1 (day of the intervention).
|
Assessment of the relaxation of the internal anal sphincter
Time Frame: day 1, day +7, day +56
|
Measurement of the relaxation using MAPLe
|
day 1, day +7, day +56
|
Assessment of the incontinence
Time Frame: day 1, day +7, day +56
|
Score of Vaizey (0 minimum score, perfect continence; 24 = maximum score, totally incontinent)
|
day 1, day +7, day +56
|
Assessment of the healing rate
Time Frame: day 1, day +56
|
Assessment according to the Lindsey criteria
|
day 1, day +56
|
Safety of the procedure by assessing adverse events, device deficiencies and identifying new risks
Time Frame: day 1, day +7, day +56
|
Safety of the procedure by assessing adverse events (description of adverse events, number of participants), device deficiencies (description of the deficiency) and identifying new risks
|
day 1, day +7, day +56
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dieter Hahnloser, Prof., Lausanne Universitaire Hospital (CHUV)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DIT_Anuscope_2019
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anal Fissure
-
State Scientific Centre of Coloproctology, Russian...Recruiting
-
Istanbul Medipol University HospitalCompletedAnal Fissure ChronicTurkey
-
Treviso Regional HospitalCompletedAnal Fissure | Anal Fissure ChronicItaly
-
Mansoura UniversityCompleted
-
Zagazig UniversityCompletedChronic Anal FissureEgypt
-
University of NinevehCompleted
-
Mansoura UniversityCompleted
-
Hospital General Universitario ElcheCompletedChronic Anal FissureSpain
-
Hvidovre University HospitalUnknownFocus: Anal Incontinence After Lateral Sphincterotomy for Chronic Anal FissureDenmark
-
KTO Karatay UniversityIstanbul Medipol University HospitalCompletedPRP | Anal Fissure ChronicTurkey
Clinical Trials on Anuscope with needles
-
Heidelberg UniversityUnknown
-
Cliniques universitaires Saint-Luc- Université...CompletedChronic Hemodialysis Patients | Vascular Abord: Native Arterio-venous Fistula | Buttonhole CannulationBelgium
-
Columbia UniversitySociety of Family PlanningCompleted
-
Chang Gung Memorial HospitalCompleted
-
Rambam Health Care CampusCompleted
-
Columbia UniversityCompleted
-
Aarhus University Hospital SkejbyRingkjøbing County Research Fond; Union of Midwives Research Fond; Skejby Research...CompletedPregnancy Overdue - Week 41+6
-
NYU Langone HealthTerminatedProstate CancerUnited States
-
Boston Scientific CorporationTerminatedPain | Pancreatic CancerUnited States
-
The Cleveland ClinicCompletedEpidural PlacementUnited States